Yoshito Mizoguchi

Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Objective: Electroconvulsive therapy (ECT) is utilized for treating psychiatric disorders, such as schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BD). We aimed to compare pre- and post-ECT treatment outcomes between patients with SCZ and a combined group of patients with MDD and BD (MDD+BD) to assess the distinction between the antipsychotic and antidepressant effects of ECT. Methods: ECT was administered to patients with SCZ (n = 17) and those with MDD+BD (n = 7). Symptoms were evaluated using the brief psychiatric rating scale (BPRS), clinical global impression scale (CGI), and global assessment of functioning (GAF). Plasma brain-derived neurotrophic factor (BDNF) levels were also measured. Results: The BPRS, CGI, and GAF scores significantly differed after ECT compared with those before ECT in each patient group. However, no significant differences were observed between the groups for each disorder. No significant differences were observed in plasma BDNF levels between the groups at baseline and during ECT. At baseline, only depression scores were more favorable in the SCZ group, whereas positive symptoms and disorganization scores were higher in the MDD+BD group. During treatment, positive symptoms, activation, and disorganization items were significantly more favorable in the MDD+BD group compared with the SCZ group. Total BPRS scores were not associated with plasma BDNF levels; however, rating scores of the several items related to activation, resistance, and disorganization were positively correlated with BDNF levels. Conclusion: ECT effects on several clinical outcomes in the MDD+BD group were associated with plasma BDNF levels. These findings suggest that ECT may be more effective for treating MDD than SCZ.

Year:

2025

Electroconvulsive therapy (ECT) is utilized for treating psychiatric disorders such as schizo-phrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BD). To assess the comparative clinical efficacy and acceptability of ECT, pre- and post-treatment comparisons were conducted between groups of patients with SCZ and combined groups of patients with depression plus bipolar disorder (MDD+BD). ECT was administered to SCZ (n = 17), and MDD+BD (n = 7) patients. Symptom were evaluated using the Brief Psychiatric Rating Scale (BPRS), and plasma brain-derived neurotrophic factor (BDNF) levels were measured. While statistically significant differences were observed in the rating scales before ECT compared to those after ECT for each patient group, no significant change between the groups for each disorder was observed. Additionally, there were no significant differences in plasma BDNF levels between the groups at baseline and during the ECT. To estimate the difference between the SCZ and MDD + BD groups, we reanalyzed the 24 individual BPRS items. At baseline, only depression scores indicated favor towards SCZ, while positive symptoms and disorganization scores suggested a favorable condition in the MDD + BD group. During treatment, positive symptoms, activation and disorganization items showed favor in the MDD + BD groups compared to the SCZ group. The total BPRS scores were not associated with the plasma BDNF levels; however, rating scores of the several items in the activation, resistance and disorganization were positively correlated with BDNF levels. In conclusion, although ECT was effective for patients with both SCZ and MDD+BD, the pos-itive symptoms, activation, and disorganization responses to ECT were statistically higher in MDD+BD than in SCZ, with the exception of depressive behavior. Additionally, the ECT ef-fects for several clinical outcomes of MDD+BD were associated with plasma BDNF levels. These findings suggest that ECT may be even more effective for MDD than for SCZ.

Year:

2024

Background The noradrenergic systems in the brain maintain cognitive functions including attention/concentration and establishment of long‐term memory. In addition, hypofunction of noradrenergic systems is supposed to be involved in the pathophysiology of Alzheimer's disease. In this study, we tried to examine the possible associations of concentrations of basal salivary 3‐methoxy‐4‐hydroxyphenylglycol (sMHPG), a major metabolite of noradrenaline, and brain volume changes during 4 years in elderly people living in a rural community. Methods The survey was conducted twice in Kurokawa‐cho, Imari, Saga Prefecture, Japan, among people aged 65 years and older. We collected data from 226 residents. Measurements of sMHPG and brain MRIs were collected at Time 1 (2005–2007). Follow‐up brain MRIs were taken at Time 2 (2009–2011). A total of 70 participants (18 men, mean age 71.9 ± 4.8 years; 52 women, mean age 72.0 ± 4.3 years) completed this survey. Concentrations of sMHPG at baseline were divided into two groups using the mean value (12.83 ng/ml). We compared the brain volumes between groups with higher and lower sMHPG concentrations over time using voxel‐based morphometry implemented with statistical parametric mapping. Results In participants with higher sMHPG concentrations at baseline, brain volumes including right precuneus were significantly larger 4 years after baseline than those with lower sMHPG concentrations at baseline. No interaction between sMHPG concentration and MRI acquisition interval was found. Conclusion Our results suggest that higher sMHPG concentrations in elderly people might be associated with maintenance of brain volume, especially in brain regions closely related to cognitive function.

Year:

2023

Collaborators (2)

Takefumi Ueno

Clinical Professor

Kyushu University

JAPAN
View details

Ryuzo Orihashi

Saga University

JAPAN
View details